Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pancreatic cancer.

S J Cohen1, W H Pinover, J C Watson

  • 1Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paraphimosis.

The Southern medical record·2022
Same author

Fracture of the Clavicle.

Atlanta medical and surgical journal·2022
Same author

Patient-physician discordance in goals of care for patients with advanced cancer.

Current oncology (Toronto, Ont.)·2020
Same author

Into the Wild, Out of the Woods: A Systematic Case Study on Facilitating Emotional Change.

International journal of offender therapy and comparative criminology·2019
Same author

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Optimal pancreatic cancer treatment involves surgery, adjuvant therapy, and symptom management. Multidisciplinary care at high-volume centers improves outcomes, but long-term survival remains poor, emphasizing clinical trial participation.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Gastroenterology

Background:

  • Pancreatic adenocarcinoma presents significant treatment challenges.
  • Optimal management requires a comprehensive, multidisciplinary approach.

Purpose of the Study:

  • To outline current best practices for pancreatic adenocarcinoma treatment.
  • To emphasize the importance of surgical resection and adjuvant therapies.
  • To highlight palliative care and clinical trial enrollment.

Main Methods:

  • Review of established treatment guidelines for pancreatic cancer.
  • Integration of surgical, oncological, and supportive care strategies.
  • Focus on patient outcomes and symptom management.

Main Results:

Related Experiment Videos

  • Surgical resection with clear margins is crucial for optimal outcomes.
  • Adjuvant chemotherapy and radiation improve outcomes for resected tumors.
  • Combined modality treatment is recommended for unresectable tumors.
  • Gemcitabine offers modest survival benefits and symptom relief in metastatic disease.

Conclusions:

  • Multidisciplinary care in high-volume centers enhances patient outcomes.
  • Symptom management (pain, anorexia, jaundice) is essential for all patients.
  • Enrollment in clinical trials is vital due to poor long-term survival rates across all stages.